Comprehensive Overview of Muscle Spasticity Drug Development Pipeline 2025

DelveInsight's 2025 comprehensive examination of the Muscle Spasticity therapeutic development landscape presents detailed information on over 15 pharmaceutical organizations and their pipeline candidates. This evaluation encompasses drug candidate profiles spanning various development phases, from preclinical research through clinical investigation. The assessment includes analysis of therapeutic candidates by formulation classification, developmental stage, delivery method, and molecular structure, while also documenting terminated development initiatives.

Interested in discovering the most recent developments in the Muscle Spasticity Pipeline? Access comprehensive information on therapeutic candidates and ongoing clinical investigations @ Muscle Spasticity Pipeline Outlook Report

Primary Findings from the Analysis

On December 05, 2025, Celgene revealed a Phase 2, randomized, double-blind, four-arm, placebo-controlled, multicenter investigation evaluating the effectiveness, safety, and tolerability of three dosage levels of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for managing spasticity in individuals with Multiple Sclerosis (BALANCE-MSS-1).

On December 04, 2025, Merz Pharmaceuticals GmbH launched an investigation to ascertain whether a single administration of 400 Units NT 201 (botulinum toxin) demonstrates superiority over placebo (inactive treatment) for addressing lower limb spasticity resulting from stroke or traumatic brain injury (Main Period). Study participants will be randomly allocated to treatment groups, and neither participants nor research personnel will be aware of the assignments.

On December 04, 2025, Ipsen commenced a Phase I/II investigation to evaluate the safety and effectiveness of escalating dosages of IPN10200, with objectives to assess the Pharmacodynamics (PD) characteristics of IPN10200 and determine the optimal IPN10200 dose(s) providing the most favorable efficacy/safety balance for treating Adult upper limb (AUL) spasticity.

The analysis demonstrates a vibrant development environment with over 15 active entities pursuing more than 15 therapeutic candidates for Muscle Spasticity management.

Prominent pharmaceutical developers include Saol Therapeutics, Daewoong Pharmaceutical, AbbVie, Supernus Pharmaceuticals, Revance Therapeutics, Ipsen, Abide Therapeutics, Motor Pharma, BetterLife Pharma, RVL Pharmaceuticals, and additional organizations.

Notable pipeline therapies encompass CORETOX®, BOTOX®, XP19986 SR1, 10 mg BID, Meditoxin, Tizanidine (sublingual or oral), SPARC0921, IPN10200, Arbaclofen, and other compounds.

Seeking insights into which pharmaceutical organizations are driving innovation in Muscle Spasticity treatment? Explore the complete pipeline analysis @ Muscle Spasticity Clinical Trials Assessment

This comprehensive evaluation delivers a condition synopsis, pipeline landscape, and therapeutic appraisal of prominent pipeline candidates within this medical domain, while identifying unmet clinical requirements associated with Muscle Spasticity.

Understanding Muscle Spasticity

Muscle spasticity represents a medical condition characterized by muscle stiffness, rigidity, and impaired control resulting from persistent, involuntary muscle contractions. This occurs when neural signals governing muscle movement experience disruption, generally due to central nervous system damage affecting the brain or spinal cord. Consequently, impacted muscles demonstrate resistance to movement, rendering activities such as ambulation, stretching, or postural maintenance difficult. Spasticity frequently manifests in neurological conditions including cerebral palsy, multiple sclerosis, spinal cord trauma, stroke, and traumatic brain injury.

Emerging Therapeutic Candidates

Arbaclofen ER: Janssen Pharmaceutical

Arbaclofen ER represents an extended-release formulation of arbaclofen, the R stereoisomer of baclofen, utilizing the proprietary Osmodex® drug delivery platform and undergoing investigation for managing spasticity associated with multiple sclerosis.

Lu AG06466: Abide Therapeutics

Lu AG06466 (previously designated ABX 1431) is an orally administered, small molecule compound under development by Abide Therapeutics (currently Lundbeck A/S), targeting neuropathic pain, irritable bowel syndrome-related pain, multiple sclerosis-associated spasticity [muscle spasticity in developmental records], fibromyalgia, and epilepsy.

Monitoring active Muscle Spasticity Clinical trials? This information is essential reading. Discover the latest breakthrough developments @ Muscle Spasticity Treatment Drugs

Analytical Coverage

The analysis provides comprehensive information on organizations developing therapeutic interventions for Muscle Spasticity management, including total therapeutic programs pursued by individual companies.

It evaluates diverse therapeutic candidates organized into early-phase, intermediate-phase, and advanced-phase development for Muscle Spasticity treatment.

Organizations engaged in Muscle Spasticity drug development are pursuing targeted therapeutic advancement with corresponding active and inactive (suspended or discontinued) programs.

Pipeline candidates are categorized according to developmental stage, delivery route, receptor target, single-agent or combination strategy, mechanism of action, and molecular classification.

Comprehensive examination of partnerships (inter-organizational and academic-industry collaborations), licensing agreements, and funding details supporting future market progression.

Participating Organizations

Saol Therapeutics, Daewoong Pharmaceutical, AbbVie, Supernus Pharmaceuticals, Revance Therapeutics, Ipsen, Abide Therapeutics, Motor Pharma, BetterLife Pharma, RVL Pharmaceuticals, and additional entities.

Delivery Routes

The analysis organizes pipeline therapies by administration method, including:

Oral, Intravenous, Subcutaneous

Molecular Classifications

Pipeline products are arranged under various molecular categories including:

Small molecule, Cell Therapy, Peptides, Polymer, Small molecule, Gene therapy

Covering everything from emerging therapeutic candidates to competitive intelligence, the Muscle Spasticity Pipeline Report offers comprehensive insights – explore it today @ Muscle Spasticity Market Drivers and Barriers, and Future Perspectives

Analysis Parameters

Geographic Coverage: Global

Participating Companies: Saol Therapeutics, Daewoong Pharmaceutical, AbbVie, Supernus Pharmaceuticals, Revance Therapeutics, Ipsen, Abide Therapeutics, Motor Pharma, BetterLife Pharma, RVL Pharmaceuticals, and others

Pipeline Therapies: CORETOX®, BOTOX®, XP19986 SR1, 10 mg BID, Meditoxin, Tizanidine (sublingual or oral), SPARC0921, IPN10200, Arbaclofen, and additional candidates

Therapeutic Classification by Formulation Type: Single-agent, Combination, Single-agent/Combination

Therapeutic Classification by Development Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Maintain your competitive advantage in Healthcare Research – uncover what lies ahead for the Muscle Spasticity Treatment landscape through this detailed examination @ Muscle Spasticity Emerging Drugs and Major Players

Content Structure

1. Introduction

2. Executive Summary

3. Muscle Spasticity: Overview

4. Pipeline Therapeutics

5. Therapeutics Assessment

6. Muscle Spasticity– DelveInsight’s Analytical Perspective

7. Late Stage Products (Preregistration)

8. Arbaclofen ER: RVL Pharmaceuticals

9. Mid Stage Products (Phase II)

10. SIL1002: Saol Therapeutics

11. Drug profiles in the detailed report…..

12. Early Stage Products (Phase I)

13. Lu AG06466: Abide Therapeutics

14. Drug profiles in the detailed report…..

15. Preclinical Stage Products

16. Inactive Products

17. Muscle Spasticity Key Companies

18. Muscle Spasticity Key Products

19. Muscle Spasticity- Unmet Needs

20. Muscle Spasticity- Market Drivers and Barriers

21. Muscle Spasticity- Future Perspectives and Conclusion

22. Muscle Spasticity Analyst Views

23. Muscle Spasticity Key Companies

24. Appendix

About Us

DelveInsight operates as a premier healthcare-oriented market research and advisory organization delivering superior market intelligence and analytical insights to facilitate strategic business planning. Supported by veteran industry professionals and extensive expertise in life sciences and healthcare sectors, the organization provides customized research solutions and strategic insights to clients internationally.

Contact Us

Kanishk

kkumar@delveinsight.com